GlassScriptPhysician profile
Minu Rowther
NPI 1437212487
$2,618.08
in general payments reported to CMS, 2019-2025
28 companies · $519 in 2025
The $519 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $254 · 2021: $442 · 2022: $360 · 2023: $373 · 2024: $288 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.78 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $250.75 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $219.50 | 2023-2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $217.93 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $167.71 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $147.41 | 2021-2022 | |
| Coopersurgical, INC. | $137.06 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $129.78 | 2019-2025 | |
| Organon LLC | $98.71 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $86.07 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $81.26 | 2019-2021 | |
| Duchesnay USA Incorporated | $81.21 | 2019-2020 | |
| Minerva Surgical, INC | $79.35 | 2021 | |
| Pfizer INC. | $57.27 | 2022-2023 | |
| Evofem Biosciences, INC. | $53.53 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $52.30 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $51.82 | 2019-2021 | |
| Avion Pharmaceuticals | $48.63 | 2019-2020 | |
| Exeltis, USA INC. | $45.96 | 2025 | Slynd |
| Vertical Pharmaceuticals, LLC | $34.97 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $26.33 | 2021 | |
| Sage Therapeutics, LLC | $21.84 | 2025 | Zurzuvae |
| Medtronic, INC. | $19.94 | 2025 | Closurefast |
| Intuitive Surgical, INC. | $18.76 | 2022 | |
| Glaxosmithkline, LLC. | $17.06 | 2025 | Arexvy, Shingrix |
| Millicent US INC | $15.83 | 2019 | |
| Allergan, INC. | $14.74 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minu Rowther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.